EGFR Fusion

CI-VAR-00001348Explore in graph →CIViC 4300

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
KIF5B::EGFR Fusion	Afatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11026 Case report of a 50-year-old male with Stage 1 Lung adenocarcinoma. NGS detected the presence of KIF5B::EGFR fusion (exon 15 and exon 18). The patient received two cycles of chemotherapy but experienc… (full text at CIViC) PMID 34163176 · Wang et al., 2021 · Open in CIViC	civic
KIF5B::EGFR Fusion	Afatinib + BevacizumabCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID12367 This case study reports the first case of a KIF5B-EGFR fusion (KIF5B exon 15–EGFR exon 18) in primary lung adenocarcinoma. The patient showed a significant partial response to afatinib and bevacizumab… (full text at CIViC) PMID 32903808 · Xu et al., 2020 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.